

CARACO PHARMACEUTICAL LABORATORIES LTD

Form 8-K/A

November 05, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K/A**  
(Amendment No. 1)

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

January 19, 2007  
(Date of report)

**CARACO PHARMACEUTICAL LABORATORIES, LTD.**

---

(Exact name of registrant as specified in its charter)

Michigan

0-24676

38-2505723

---

(State or other jurisdiction  
of incorporation)

(Commission file number)

(I.R.S. employer  
identification no.)

1150 Elijah McCoy Drive, Detroit, Michigan 48202

---

(Address of principal executive offices)

(313) 871-8400

---

(Registrant's telephone number, including area code)

Not Applicable

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Explanatory Footnote

The registrant filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (the SEC) on January 24, 2007, disclosing that on January 19, 2007, the registrant had entered into a three-year marketing agreement with Sun Pharmaceutical Industries Limited, its majority shareholder, and included as Exhibit 10.20 thereto, the marketing agreement, portions of which had been omitted pursuant to a confidential treatment request submitted to the SEC. Pursuant to comments received from the SEC, registrant hereby amends the Form 8-K and files an amended version of Exhibit 10.20 which reduces the omitted portions of the marketing agreement.

**Item 9.01. Financial Statements and Exhibits**

c) Exhibits.

Exhibit No.      Description

10.20                      Marketing agreement between Caraco Pharmaceutical Laboratories, Ltd. and Sun Pharmaceutical Laboratories Limited. dated January 19, 2007.\*

\* Filed herewith. Certain portions of this agreement have been omitted based on a request for confidential treatment submitted to the SEC. The non-public information that has been omitted from the agreement has been separately filed with the SEC. Each redacted portion of the agreement is indicated by a [ \* ] and is subject to the request for confidential treatment submitted to the SEC. The redacted information is confidential information of the registrant and Sun Pharmaceutical Industries Limited.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CARACO PHARMACEUTICAL LABORATORIES, LTD.**

Date: October 31, 2007

By: /s/ Daniel H. Movens

\_\_\_\_\_  
Daniel H. Movens  
Chief Executive Officer

**Exhibit Index**

<u>Exhibit No.</u>	<u>Description</u>
10.20	<u>Marketing agreement between Caraco Pharmaceutical Laboratories, Ltd. and Sun Pharmaceutical Laboratories Industries dated January 19, 2007.*</u>

\*Filed herewith. Certain portions of this agreement have been omitted based on a request for confidential treatment submitted to the SEC. The non-public information that has been omitted from the agreement has been separately filed with the SEC. Each redacted portion of the agreement is indicated by a [ \* ] and is subject to the request for confidential treatment submitted to the SEC. The redacted information is confidential information of the registrant and Sun Pharmaceutical Industries Limited.